EUVIMEDEUVIMED entdecken
Crossref

Sitagliptin synergizes 5‐fluorouracil efficacy in colon cancer cells through MDR1‐mediated flux impairment and down regulation of NFκB2 and p‐AKT survival proteins

Asmaa Eisa iD, Shaden M Hanafy iD, Hany Khalil iD, Mohamed F Elshal iD

Journal of Biochemical and Molecular Toxicology · 2024

DOI: 10.1002/jbt.23796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Asmaa Eisa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Department, Genetic Engineering and Biotechnology Institute, University of Sadat City, Sadat City, Egypt. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Fluorouracil, Colonic Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5‐fluorouracil (5‐FU) is an inexpensive treatment for colon cancer; however, its efficacy is limited by chemoresistance. This study investigates the combination therapy approach of 5‐FU with Sitagliptin (Sita), a diabetic drug with potential cancer‐modulating effects. The combination was evaluated in vitro and in silico, focusing on the effects of Sita and 5‐FU on colon cancer cells. The results showed that the addition of Sita significantly decreased the IC50 of 5‐FU compared to 5‐Fu monotherapy. The study also found that Sita and 5‐FU interact synergistically, with a combination index below 1. Sita successfully lowered the 5‐FU dosage reduction index, decreasing the expression of MDR1 mRNA and p‐AKT and NFκB2 subunits p100/p52 protein. Molecular docking analyses confirmed Sita's antagonistic action on MDR1 and thymidylate synthase proteins. The study concludes that sitagliptin can target MDR1, increase apoptosis, and significantly reduce the expression of p‐AKT and NFκB2 cell‐survival proteins. These effects sensitize colon cancer cells to 5‐FU. Repurposing sitagliptin may enhance the anticancer effects of 5‐FU at lower dosages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sitagliptin PhosphateFluorouracilColonic NeoplasmsProto-Oncogene Proteins c-aktATP Binding Cassette Transporter, Subfamily BDrug SynergismHumansDown-RegulationCell Line, TumorMolecular Docking Simulation

Stichwörter der Autor:innen

5‐flourouracilapoptosischemoresistancemolecular dockingsitagliptin

Substanzen

Sitagliptin PhosphateFluorouracilProto-Oncogene Proteins c-aktATP Binding Cassette Transporter, Subfamily BABCB1 protein, human

Autor:innen und Institutionen

  • Molecular Biology Department, Genetic Engineering and Biotechnology Institute, University of Sadat City, Sadat City, Egypt.

ORCID-Profile: Asmaa Eisa, Shaden M Hanafy, Hany Khalil, Mohamed F Elshal

Zitieren

APA

Eisa, A., Hanafy, S. M., Khalil, H., & Elshal, M. F. (2024). Sitagliptin synergizes 5‐fluorouracil efficacy in colon cancer cells through MDR1‐mediated flux impairment and down regulation of NFκB2 and p‐AKT survival proteins. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23796

Vancouver

Eisa A, Hanafy SM, Khalil H, Elshal MF. Sitagliptin synergizes 5‐fluorouracil efficacy in colon cancer cells through MDR1‐mediated flux impairment and down regulation of NFκB2 and p‐AKT survival proteins. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23796

BibTeX
@article{Eisa2024,
  author = {Eisa, Asmaa and Hanafy, Shaden M and Khalil, Hany and Elshal, Mohamed F},
  title = {Sitagliptin synergizes 5‐fluorouracil efficacy in colon cancer cells through MDR1‐mediated flux impairment and down regulation of NFκB2 and p‐AKT survival proteins},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2024},
  doi = {10.1002/jbt.23796}
}
Kostenlos starten →